RVX-297
规格
| Cas Number | 1044871-04-6 |
| 规格或纯度 | ≥96% |
| 纯度 | ≥96% |
| 包装 | 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 50 mg/mL (118.06 mM; Need ultrasonic) |
| 过滤标签 | 表观遗传学,Epigenetic Reader Domain |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | RVX-297 是一种强效的口服活性 BET 溴结构域抑制剂，对 BD2 具有选择性。RVX-297 对 BRD2（BD2）、BRD3（BD2）和 BRD4（BD2）的 IC 50 s 分别为 0.08、0.05 和 0.02 μM。RVX-297 可抑制多种免疫缺陷病毒的炎症基因表达 |
| 英文描述 |
RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for BD2. RVX-297 shows IC 50 s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD4(BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models. In Vitro RVX-297 (1-30 μM; 24 hours) decreases proinflammatory gene expression in synovial fibroblasts. RVX-297 displaces BET proteins from the promoters of sensitive genes and disrupted recruitment of active RNA polymerase II, a property shared with pan-BET inhibitors that nonselectively bind BET BDs. RVX-297 reduces gene expression of inflammatory mediators in vitro. RVX-297 suppresses IL-6 gene induction in human U937 macrophages, mouse primary B cells isolated from the spleen, mouse BMDMs, and THP-1 monocytes in a dose-dependent manner. RVX-297 represses IL-1β expression in LPS-stimulated mouse BMDMs, with an IC 50 of 0.4-3 μM. RVX-297 inhibits MCP-1 expression in unstimulated human PBMCs with an IC 50 of 0.4 μM. RVX-297 inhibits antigen stimulation of T cells and the induction of IL-17 expression. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRCell Line: Synovial fibroblasts Concentration: 1-30 μM Incubation Time: 24 hours Result: Downregulated IL-6 and VCAM-1 gene expression in synovial fibroblasts. In Vivo RVX-297 (25-75 mg/kg; p.o.; per day for 6 day) inhibits progression of pathology in the rat collagen-induced arthritis model . RVX-297 (75-150 mg/kg) inhibits progression of pathology in the mouse collagen-induced arthritis model . RVX-297 suppresses cytokine production in LPS-treated mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Lewis rats are 6-8 weeks old, approximately 150 g (rat collagen-induced arthritis) Dosage: 25, 50, and 75 mg/kg Administration: P.o.; per day for 6 days Result: Prevented swelling and inflammation of the ankle and knee joints. Form:Solid |